phthalimide conjugation strategy vivo target protein degradation
development effective pharmacological inhibitors multidomain scaffold proteins notably transcription factors particularly challenging problem part many small-molecule antagonists disrupt activity one domain target protein devised chemical strategy promotes ligand-dependent target protein degradation using example transcriptional coactivator brd4 protein critical cancer cell growth survival appended competitive antagonist bet bromodomains phthalimide moiety hijack cereblon e3 ubiquitin ligase complex resultant compound dbet1 induced highly selective cereblon-dependent bet protein degradation vitro vivo delayed leukemia progression mice second series probes resulted selective degradation cytosolic protein fkbp12 chemical strategy controlling target protein stability may implications therapeutically targeting previously intractable proteins
